RICHMOND, Calif., Sept. 29, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate in the following conferences in October.
- 2016 Cell & Gene Meeting on the Mesa, La Jolla, CA, October 5-7, 2016
Dr. Macrae will participate in a panel discussion on gene editing at 10:30 am PT on Wednesday, October 5th, and is scheduled to present a company overview during the annual Partnering Forum at 1:00 pm PT on Thursday, October 6th.
The presentation will be webcast live on the conference website and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentation. A replay of the presentation will be published on ARM's website after the event.
- Jefferies Gene Editing/Therapy Summit, New York, NY, October 11, 2016
Dr. Macrae is scheduled to present at 8:20 am ET and will participate in a panel discussion at 10:00 am ET on Tuesday, October 11th.
Webcasting services are not provided at this meeting.
About the Cell & Gene Meeting on the Mesa
Organized by the Alliance for Regenerative Medicine (ARM) and the Sanford Consortium for Regenerative Medicine, this event is the largest partnering meeting organized specifically for the cell and gene therapy and regenerative medicine sector. This year's meeting will attract more than 800 attendees, including senior executives from leading cell therapy, gene therapy and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations and disease philanthropies, life science media and more.
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures® for monogenic and infectious diseases by deploying its novel zinc finger DNA-binding protein technology, in therapeutic genome editing and gene regulation, and AAV-based gene therapy platforms. The Company's proprietary ZFN-mediated in vivo genome editing approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its in vivo genome editing approach, Sangamo is initiating a Phase 1/2 clinical trial for hemophilia B, the first in vivo genome editing application cleared by the FDA. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sangamo-biosciences-announces-participation-at-upcoming-investor-conferences-300336721.html
SOURCE Sangamo BioSciences, Inc.